|
|
| (One intermediate revision by the same user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Ezetimibe]] |
| {{Ezetimibe}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Drug Interactions==
| |
| ===[[cyclosporine]]===
| |
| | |
| Caution should be exercised when using ZETIA and [[cyclosporine]] concomitantly due to increased exposure to both ezetimibe and [[cyclosporine]]. [[cyclosporine]] concentrations should be monitored in patients receiving ZETIA and [[cyclosporine]].
| |
| | |
| The degree of increase in ezetimibe exposure may be greater in patients with severe [[renal insufficiency]]. In patients treated with [[cyclosporine]], the potential effects of the increased exposure to ezetimibe from concomitant use should be carefully weighed against the benefits of alterations in lipid levels provided by ezetimibe.
| |
| | |
| ===Fibrates===
| |
| | |
| The efficacy and safety of coadministration of ezetimibe with [[fibrates]] other than [[fenofibrate ]]have not been studied.
| |
| | |
| [[Fibrates]] may increase cholesterol excretion into the bile, leading to cholelithiasis. In a preclinical study in dogs, ezetimibe increased cholesterol in the gallbladder bile [seeNonclinical Toxicology (13.2)]. Coadministration of ZETIA with [[Fibrates]] other than [[fenofibrate]] is not recommended until use in patients is adequately studied.
| |
| | |
| ===Fenofibrate===
| |
| | |
| If cholelithiasis is suspected in a patient receiving ZETIA and [[fenofibrate]], gallbladder studies are indicated and alternative lipid-lowering therapy should be considered [seeAdverse Reactions (6.1) and the product labeling for [[fenofibrate]].
| |
| | |
| ===Cholestyramine===
| |
| | |
| Concomitant [[cholestyramine ]]administration decreased the mean area under the curve (AUC) of total ezetimibe approximately 55%. The incremental LDL-C reduction due to adding ezetimibe to cholestyramine may be reduced by this interaction.
| |
| | |
| ===Coumarin Anticoagulants===
| |
| | |
| If ezetimibe is added to [[warfarin]], a coumarin [[anticoagulant]], the [[International Normalized Ratio ]]([[INR]]) should be appropriately monitored.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ZETIA (EZETIMIBE) TABLET [MERCK SHARP & DOHME CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a773b0b2-d31c-4ff4-b9e8-1eb2d3a4d62a | publisher = | date = | accessdate = 11 February 2014 }}</ref></div>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Hypolipidemic agents]]
| |
| [[Category:Lactams]]
| |
| [[Category:Merck]]
| |
| [[Category:Schering-Plough]]
| |
| [[Category:Azetidines]]
| |
| [[Category:Organofluorides]]
| |
| [[Category:Phenols]]
| |
| [[Category:Cardiovasuclar Drugs]]
| |
| [[Category:Drugs]]
| |